IL318073A - PRMT5 inhibitors and their uses - Google Patents
PRMT5 inhibitors and their usesInfo
- Publication number
- IL318073A IL318073A IL318073A IL31807324A IL318073A IL 318073 A IL318073 A IL 318073A IL 318073 A IL318073 A IL 318073A IL 31807324 A IL31807324 A IL 31807324A IL 318073 A IL318073 A IL 318073A
- Authority
- IL
- Israel
- Prior art keywords
- prmt5 inhibitors
- prmt5
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823374P | 2019-03-25 | 2019-03-25 | |
| US201962874773P | 2019-07-16 | 2019-07-16 | |
| PCT/US2020/024654 WO2020198323A1 (en) | 2019-03-25 | 2020-03-25 | Prmt5 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318073A true IL318073A (en) | 2025-02-01 |
Family
ID=72609147
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318073A IL318073A (en) | 2019-03-25 | 2020-03-25 | PRMT5 inhibitors and their uses |
| IL286622A IL286622A (en) | 2019-03-25 | 2021-09-23 | Prmt5 inhibitors and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286622A IL286622A (en) | 2019-03-25 | 2021-09-23 | Prmt5 inhibitors and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12583859B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3947387B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7609798B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220023330A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114127072B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020245480A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021019125A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134779A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL318073A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011524A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202110272SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020198323A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| EP3947387B1 (en) | 2019-03-25 | 2024-10-23 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677B (zh) | 2020-07-31 | 2026-07-28 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| CN117157297B (zh) * | 2021-07-20 | 2026-06-16 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
| WO2023127857A1 (ja) * | 2021-12-27 | 2023-07-06 | 株式会社理研ジェネシス | 新規人工核酸、その製造方法及び用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| CA2903394C (en) * | 2013-03-14 | 2021-08-31 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EA031895B1 (ru) | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
| TWI730980B (zh) * | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| CN108884108B (zh) * | 2016-03-10 | 2021-08-31 | 詹森药业有限公司 | 用于用作prmt5抑制剂的取代核苷类似物 |
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018160824A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| MA49840A (fr) * | 2017-08-09 | 2020-06-17 | Prelude Therapeutics Inc | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| MX2020005944A (es) * | 2017-12-08 | 2020-08-24 | Janssen Pharmaceutica Nv | Analogos espirobiciclicos novedosos. |
| EP3947387B1 (en) | 2019-03-25 | 2024-10-23 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
-
2020
- 2020-03-25 EP EP20778402.6A patent/EP3947387B1/en active Active
- 2020-03-25 BR BR112021019125A patent/BR112021019125A2/pt not_active IP Right Cessation
- 2020-03-25 KR KR1020217034437A patent/KR20220023330A/ko not_active Ceased
- 2020-03-25 MX MX2021011524A patent/MX2021011524A/es unknown
- 2020-03-25 JP JP2021557342A patent/JP7609798B2/ja active Active
- 2020-03-25 CA CA3134779A patent/CA3134779A1/en active Pending
- 2020-03-25 WO PCT/US2020/024654 patent/WO2020198323A1/en not_active Ceased
- 2020-03-25 IL IL318073A patent/IL318073A/en unknown
- 2020-03-25 SG SG11202110272SA patent/SG11202110272SA/en unknown
- 2020-03-25 AU AU2020245480A patent/AU2020245480A1/en not_active Abandoned
- 2020-03-25 US US17/598,152 patent/US12583859B2/en active Active
- 2020-03-25 CN CN202080037608.5A patent/CN114127072B/zh active Active
-
2021
- 2021-09-23 IL IL286622A patent/IL286622A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114127072A (zh) | 2022-03-01 |
| KR20220023330A (ko) | 2022-03-02 |
| AU2020245480A1 (en) | 2021-11-11 |
| CA3134779A1 (en) | 2020-10-01 |
| EP3947387B1 (en) | 2024-10-23 |
| US20220194949A1 (en) | 2022-06-23 |
| IL286622A (en) | 2021-12-01 |
| SG11202110272SA (en) | 2021-10-28 |
| JP2022521818A (ja) | 2022-04-12 |
| EP3947387A1 (en) | 2022-02-09 |
| EP3947387A4 (en) | 2022-11-30 |
| WO2020198323A1 (en) | 2020-10-01 |
| BR112021019125A2 (pt) | 2021-11-30 |
| US12583859B2 (en) | 2026-03-24 |
| MX2021011524A (es) | 2021-12-15 |
| CN114127072B (zh) | 2024-10-11 |
| JP7609798B2 (ja) | 2025-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202109573B (en) | Prmt5 inhibitors | |
| IL313281B1 (en) | Mta-cooperative prmt5 inhibitors | |
| IL288381A (en) | Tead inhibitors and their uses | |
| IL288384A (en) | Tead inhibitors and their uses | |
| IL282487B1 (en) | Tyk2 inhibitors and their use | |
| SG11202106520VA (en) | Kif18a inhibitors | |
| SI3999506T1 (sl) | Zaviralci PARP1 | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL282090B2 (en) | TYK2 inhibitors and their uses | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL289863A (en) | enzyme inhibitors | |
| IL289914A (en) | enzyme inhibitors | |
| IL286622A (en) | Prmt5 inhibitors and uses thereof | |
| LT3621694T (lt) | Lrrc33 inhibitoriai ir jų panaudojimas | |
| IL292198A (en) | Tim-3 inhibitors and their uses | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| IL289778A (en) | enzyme inhibitors | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL289783A (en) | enzyme inhibitors | |
| EP4076460A4 (en) | PRMT5 INHIBITORS | |
| IL280408A (en) | CDK inhibitors and uses thereof | |
| EP3833667A4 (en) | PRMT5 INHIBITORS | |
| GB201908884D0 (en) | Inhibitors and use | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors |